MADELYN COLLUM: Open Payments
NPI 1629641519 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,198 in 70 payments from 11 companies in 2025. Trend: 2023 $240 · 2024 $1,133 · 2025 $1,198
Food & beverage: $1,198
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 32 | $442 |
| Madrigal Pharmaceuticals | 5 | $187 |
| Phathom Pharmaceuticals, Inc. | 12 | $156 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $105 |
| Janssen Biotech, Inc. | 4 | $83 |
| Ardelyx, Inc. | 5 | $82 |
| Aimmune Therapeutics, Inc. | 3 | $56 |
| Regeneron Healthcare Solutions, Inc. | 1 | $38 |
| Exact Sciences Corporation | 1 | $19 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $15 |
Products named: REZDIFFRA, LINZESS, VOQUEZNA, CREON, ENTYVIO, RINVOQ, TREMFYA, IBSRELA.
Industry payments across AL — which companies pay providers there.
